Anonymous
Guest
Anonymous
Guest
FDA joins probe into Gilenya patient's sudden death
December 21, 2011 — 10:09am ET | By Tracy Staton
FDA is now investigating the death of a multiple sclerosis patient who'd just taken Gilenya for the first time. The agency joins Novartis ($NVS) in probing the 59-year-old patient's death within 24 hours of starting treatment. The patient had been monitored for 6 hours after that first dose, as required by Gilenya's label, without any apparent ill effects.
As InPharm points out, Gilenya has been tagged with some serious potential side effects
December 21, 2011 — 10:09am ET | By Tracy Staton
FDA is now investigating the death of a multiple sclerosis patient who'd just taken Gilenya for the first time. The agency joins Novartis ($NVS) in probing the 59-year-old patient's death within 24 hours of starting treatment. The patient had been monitored for 6 hours after that first dose, as required by Gilenya's label, without any apparent ill effects.
As InPharm points out, Gilenya has been tagged with some serious potential side effects